Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Tertiary Lymphoid Structures × brigimadlin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Sarcoma 1 Gastrointestinal 1 Breast 1

Conditions

Biliary Tract Neoplasms 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Tertiary Lymphoid Structures 1 Sarcoma 1 Pancreatic Neoplasms 1 Lung Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

tazemetostat 1 relatlimab 1 durvalumab 1 brigimadlin 1 bintrafusp alfa protein, human 1 Nivolumab 1 Doxorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06084689 2025-09-02

EMPIRE

Institut Bergonié

Phase 2 Withdrawn

BreastGastrointestinalSarcomaThoracic

Tertiary Lymphoid Structures, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡